A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

Completed

Conditions studied: Mouth Cancer, Lip Cancer, Throat Cancer, Lip Neoplasms, Head and Neck Cancers

In brief

1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.

Key facts

Study ID

NCT00186433

Run by

Stanford University

People needed

49

Starts

2001-11-01

Expected to finish

2013-06-01

Last updated by the study team

2015-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Having a new diagnosis of Nasopharyngeal carcinoma.
• Being treated with either radiotherapy or chemoradiotherapy for this condition.

You may not qualify if…

• Age <18 since NPC is a very rare condition in this age group and may have a different biological behavior
• Patients who are unable to provide informed consents for themselves.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.